KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. KalVista Pharmaceuticals, Inc. is not a good value stock. KalVista Pharmaceuticals, Inc. is not very popular among insiders. KalVista Pharmaceuticals, Inc. is a mediocre stock to choose.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the discovery, developm...

News

Benjamin L. Palleiko Sells 7,352 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

Zolmax KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 7,352 shares of the business's stock in a transaction that occurred on Monday, September 9th. The stock...\n more…

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Reaffirmed by Cantor Fitzgerald

Zolmax KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report)s stock had its "overweight" rating reaffirmed by equities researchers at Cantor Fitzgerald in a report issued on Monday, Benzinga...\n more…

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

Business Wire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that its management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19th...\n more…

KalVista Pharmaceuticals appoints Brian Piekos as finance chief

SeekingAlpha.com: All News no summary\n more…

KalVista Appoints Brian Piekos as Chief Financial Officer

Business Wire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a...\n more…

Cantor Fitzgerald Reaffirms "Overweight" Rating for KalVista Pharmaceuticals (NASDAQ:KALV)

Ticker Report Cantor Fitzgerald reaffirmed their overweight rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV - Free Report) in a research report sent to investors on Monday, Benzinga reports. A number of...\n more…